title: Management of dyslipidemia in patients with human immunodeficiency virus.
abstract: Dyslipidemias are more common in the patient population with human immunodeficiency virus (HIV). Combination antiretroviral therapy (ART) has dramatically reduced HIV-associated morbidity and mortality and has transformed HIV disease into a chronic, manageable condition. As a result, non-AIDS-related illnesses, including cardiovascular diseases, are now the leading causes of death in the HIV-infected population. Optimizing fasting lipid parameters plays an important role in reducing cardiovascular risk in this population. This review focuses on the management of dyslipidemia in HIV-infected individuals treated with combination ART.
authors.affiliation: Swedish Medical Center, Seattle, WA.
authors.forename: Peter
authors.initials: P
authors.lastname: Shalit
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control / Q000821:virology; D050171:Dyslipidemias / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy / Q000821:virology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D020276:HIV Long-Term Survivors; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors; D013997:Time Factors
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D008055:Lipids